Experienced in ABO Incompatibility

Jochen Buechner

Oslo, NO 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in ABO Incompatibility
Oslo, NO 
OverviewLocationsClinical Research

Overview

Jochen Buechner practices in Oslo, Norway. Mr. Buechner is rated as an Experienced expert by MediFind in the treatment of ABO Incompatibility. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Nijmegen Breakage Syndrome, Bone Marrow Transplant, and Bone Graft.

His clinical research consists of co-authoring 72 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of ABO Incompatibility.

Gender
Male

Locations

Oslo, Norway
Other Locations
Nydalen, 0424, Norway
Tromso, Norway

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug, Radiation
Study Drugs: VP16, Thiotepa, Treosulfan, Fludarabine, Busulfan, Anti-Thymocyte Globulin, Cyclophosphamide, Grafalon
Study Phase: Phase 2/Phase 3
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Biological
Study Drugs: Alemtuzumab, Fludarabine, Cyclosporine, Mycophenolate Mofetil
Study Phase: Phase 2
A Phase II Study of Blincyto in Children With CD19+ Precursor B-lineage ALL and MRD-Positivity Before and/or Following First Allogeneic HSCT
A Phase II Study of Blincyto in Children With CD19+ Precursor B-lineage ALL and MRD-Positivity Before and/or Following First Allogeneic HSCT
Enrollment Status: Terminated
Publish Date: January 16, 2024
Intervention Type: Drug
Study Drug: Blinatumomab
Study Phase: Phase 2
View 2 Less Clinical Trial

72 Total Publications

Epigenetic risk stratification in juvenile myelomonocytic leukemia by targeted methylation analysis of the BMP4 locus.
Epigenetic risk stratification in juvenile myelomonocytic leukemia by targeted methylation analysis of the BMP4 locus.
Journal: Clinical epigenetics
Published: June 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Buechner's expertise for a condition
ConditionClose
    View All 22 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile